FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPRO	VAL
OMB Number:	3235-0287
Estimated average but	urden
houre por rosponso	0.5

longer subject to
Section 16. Form 4 or
Form 5 obligations
may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	pe Response													
1. Name and Address of Reporting Person * SHERWIN STEPHEN A			2. Issuer Name and Ticker or Trading Symbol RIGEL PHARMACEUTICALS INC [RIGL]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
(Last) (First) (Middle) C/O RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD.				3. Date of Earliest Transaction (Month/Day/Year) 05/21/2014						_ Officer (giv	e title below)	Oth	er (specify below	7)
(Street) SOUTH SAN FRANCISCO, CA 94080				4. If Amendment, Date Original Filed(Month/Day/Year)					_X_	6. Individual or Joint/Group Filing(Check Applicable Line) X_ Form filed by One Reporting Person Form filed by More than One Reporting Person				
	(City) (State) (Zip)				Table I - Non-Derivative Securities Acqui					ired, Disposed of, or Beneficially Owned				
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Yes			2A. Deemed Execution Da any (Month/Day/		Code (Instr		1. Securities Acc A) or Disposed Instr. 3, 4 and 5	of (D) Own Train	Amount of Securities Beneficially Dwned Following Reported Transaction(s) Instr. 3 and 4)		d	Ownership Form: Direct (D)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
						Co	de V	Amount (A) or (D)	Price				(I) (Instr. 4)	
Reminder:	Report on a	separate line for each	n class of securities	beneficial	lly owned	airectiy	Persor	ns who respor					ned SEC 1	474 (9-02)
Reminder:	Report on a s	separate line for each	Table II -	Derivati	ive Securi	ties Acc	Persor in this display	ns who respor form are not i ys a currently osed of, or Ben	equired to valid OMB eficially Ow	respond control r	unless the		ned SEC 1	474 (9-02)
1. Title of Derivative Security (Instr. 3)	2. Conversion	3. Transaction	Table II - 3A. Deemed Execution Date, if	Derivati (e.g., put 4. Transac Code	ive Securits, calls, v 5. No of Do Secu Or D of (I	ties Accordants amber erivatives rities aired (A) sposed b) a 3, 4,	Person in this display display of the property	ns who resported form are not to a currently osed of, or Benonvertible securercisable and Date	equired to valid OMB eficially Ow	control rened d Amount	unless the number.		Ownershi Form of Derivativ Security: Direct (D or Indirec	11. Natu of Indire Benefici Ownersh (Instr. 4)
1. Title of Derivative Security	2. Conversion or Exercise Price of Derivative	3. Transaction	Table II - 3A. Deemed Execution Date, if any	Derivati (e.g., put 4. Transac Code	ive Securits, calls, v 5. Notion of D Security Acquired or D of (I (Inst	ties Accordants amber erivative rities irred (A) sposed b) - 3, 4,	Persor in this display display in this display in this display in the following in this display in the following in this display in the display in this display in the display	ns who resported form are not up a currently so a currently so osed of, or Benonvertible securerisable and Date up/Year)	equired to valid OMB eficially Own ities) 7. Title and of Underly Securities	control rened d Amount	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported	Ownershi Form of Derivativ Security: Direct (D or Indirec	11. Nature of Indire Benefici e Owners! (Instr. 4)

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
SHERWIN STEPHEN A C/O RIGEL PHARMACEUTICALS, INC. 1180 VETERANS BLVD. SOUTH SAN FRANCISCO, CA 94080	X					

Signatures

/s/ Dolly Vance (Attorney-In-Fact)	05/21/2014
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The shares vest monthly for twelve (12) months from the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.